✦ LIBER ✦

Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS

✍ Scribed by List, A F; Bennett, J M; Sekeres, M A; Skikne, B; Fu, T; Shammo, J M; Nimer, S D; Knight, R D; Giagounidis, A

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P-012 Clonal activation of Akt in low-ri

✍ Follo, M.Y.; Mongiorgi, S.; Clissa, C.; Stoyanova, M.; Paolini, S.; Quaranta, M. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 62 KB

Patients with del(5q) MDS who fail to ac

✍ Gudrun Göhring; Aristoteles Giagounidis; Guntram Büsche; Hans Heinrich Kreipe; M 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 280 KB

P-104 Outcomes by IPSS-R in lenalidomide

✍ Sekeres, M.; Swern, A.; Fenaux, P.; Greenberg, P.; Sanz, G.; Bennett, J.; Dreyfu 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 399 KB

Low RPS14 expression in MDS without 5q -

✍ Wu, Lingyun; Li, Xiao; Xu, Feng; Zhang, Zheng; Chang, Chunkang; He, Qi 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 398 KB